December 22, 2020 7:51am
Weighting sector, market, virus aid and COVID-19’s ability to recover, worry and concerns
Pre-open indications: 1 BUY, 7 SELLs and 3 any which ways to play …
What I provide is a trusted source of share pricing intelligence that ensures that investors are kept apprised of “our” universe, the RegMed/cell and gene therapy sector and its surrounding markets
A pre-open briefing on what you need to know in the session ahead!
Dow futures are UP +0.03% (+9 points), S&P futures are UP +0.24% (+9 points) and NASDAQ futures are UP +0.56% (+71 points)
U.S. stock futures are slowly edging higher early Tuesday after a volatile Monday that saw the Dow erase a 400-point decline;
EU markets are up also recovering from Monday as fear persists over new COVID-19 strain which has interrupted investor and commerce plans;
Asia Pacific markets are down finished broadly lower with shares in China leading the region. The Shanghai Composite is down 1.86% while Japan's Nikkei 225 is off 1.04% and Hong Kong's Hang Seng is lower by 0.71%. Investors fear a highly infectious new coronavirus strain as detected hit Britain could hurt global economic recovery.
Data Docket: consumer confidence, existing home sales and Gross domestic products (GDP) numbers
Tuesday’s pre-open “slight” moves come as Congress on Monday night passed a coronavirus relief and government spending package; the bill now goes to President Trump’s desk.
Monday’s night’s recap: RegMed Investors’ (RMi) closing bell:” frothy markets sought an equilibrium. Erasing earlier sector and market losses to trade in the green on Monday while lawmakers vote on a $900 billion coronavirus relief package and fright of new strain echoes.” … https://www.regmedinvestors.com/articles/11688
- The Nasdaq closed DOWN -13.12 points (-0.10%);
- The IBB closed down -0.07% and XBI closed up +1.07%;
- Sector volume STAYED-UP with 17 of the 23-upside having higher than the 3-month average volume with the increased volume of 5 of 10-downside having higher than the 3-month average volume;
- The CBOE Volatility Index (VVIX: INDEX) was up +3.59 points or +16.64% at 25.16;
- Monday’s percentage (%) of the 23-upside were +0.40% (GBT) to +29.89% (EDIT) while the 10-downside of -0.27% (SLDB) to -16.19% (QURE);
- Q4’s December, so far: 2 neutral, 3 negative and 10 positive closes
- Q4’s November: 16 positive and 3 negative closes
- Q4’s October: 1 neutral, 11 positives with 1 negative closes
- Q3: July through September: 1 neutral, 28 positive and 34 negative closes with 2 holidays
Companies in my headlights – It’s your decision; I provide an idea and context:
Biostage (BSTG) closed up +$0.09 to $1.45 with 7,282 shares traded after Friday’s -$0.12 to $1.36 with 110 shares traded after Thursday’s +$0.08 to $1.48 with 3,593 shares traded, Wednesday’s -$0.0285 to $1.39 with 786 shares traded, Tuesday’s +$0.06 to $1.42 with 3,122 shares traded and last Monday’s +$0.01 to $1.36 with 545 shares traded.
- Question#1: WHAT is the “game plan” for the nine (9)-month-old IND to start clinical trials?
- Question#2: is there an exit or endpoint to this scenario as the share price pops and dives to justify or prop the last $4.00 private placement?
- Question#3: Could there also be a … VISA involvement issue here - the United States EB-5 Immigrant Investor Visa Program offers foreign nationals and their unmarried children under 21 the ability to receive permanent residency to the USA. The minimum investment amount for EB-5 is $900,000 USD in a USCIS approved regional center’s project. Could this be another reason behind BSTG’s investment?
SELL into Strength:
Athersys (ATHX) closed up +$0.225 to $2.24 after Friday’s $2.02, Thursday’s $1.98, Wednesday’s $1.87 and last Tuesday’s $1.94 with a POSITIVE +$0.01 or +0.45%;
bluebird bio (BLUE) closed up +$1.47 to $46.19 after Friday’s $44.72, Thursday’s $4.76, Wednesday’s $44.45 and last Tuesday’s $44.36 with a POSITIVE +$0.11 or +0.24% aftermarket indication;
Cellectis SA (CLLS) closed up +$0.92 to $27.62 after Friday’s $26.70, Thursday’s $27.30, Wednesday’s $28.18 and last Tuesday’s $25.86 with a POSITIVE +$1.38 or +5% aftermarket indication;
Homology Medicine (FIXX) closed up +$0.46 to $12.80 after Friday’s $12.34, Thursday’s $11.74, Wednesday’s $11.49 and last Tuesday’s $11.23 with a NEGATIVE -$0.30 or -2.34% aftermarket indication;
Precigen (PGEN) closed up +$0.33 to $9.96 after Friday’s $9.63, Thursday’s $8.19, Wednesday’s $7.49 and last Tuesday’s $7.17 with a NEGATIVE -$0.10 or -1% aftermarket indication;
Sangamo Therapeutics (SGMO) closed up +$0.77 to $15.09 following Friday’s $14.32, Thursday’s $13.40, Wednesday’s $13.29 and last Tuesday’s $12.98 with a POSITIVE +$0.21 or +1.39% aftermarket indication;
uniQure NV (QURE) closed down -$7.44 to $38.51 after it plunged after the FDA placed its hemophilia B clinical study on hold following Friday’s $45.95, Thursday’s $48.20, Wednesday’s $47.63 and last Tuesday’s $47.86 with a POSITIVE +$0.48 or +1.25% aftermarket indication;
Gene editing companies are booming: any which way to play …
CRISPR Therapeutics (CRSP) closed up +$18.23 or +12.27% to $166.84 with a POSITIVE +$4.66 or +2.79%;
Editas Medicine (EDIT) closed up +$19.25 or +29.89% to $83.66 with a POSITIVE +$2.84 or +3.39% aftermarket indication;
Intellia Therapeutics (NTLA) closed up +$7.32 or +13.215 to $62.73 with a POSITIVE +$0.38 or +0.61% aftermarket indication;
The BOTTOM LINE: As I have been saying, investors should have locked in profits after the spotty record of recent highs. The remainder of the 2020 will be choppy trading and economic results of previous months as many relive their portfolio of risk and add new positions.
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.